Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart Peacock

Showing results (31-40 of 135) with videos related to

Pageof 14
Sort By:
Pharmacoeconomics - Open|October 11, 2023
Real-World Cost Effectiveness of a Policy of KRAS Testing to Inform Cetuximab or Panitumumab for Third-Line Therapy of Metastatic Colorectal Cancer in British Columbia, CanadaReka E Pataky, Stirling Bryan, Mohsen Sadatsafavi, et al.
BMC Health Services Research|November 2, 2018
Long-term effects of cancer on earnings of childhood, adolescent and young adult cancer survivors - a population-based study from British Columbia, CanadaPaulos Teckle, Stuart Peacock, Mary L McBride, et al.
Cancer Medicine|October 17, 2020
Understanding cancer survivors' reasons to medicate with cannabis: A qualitative study based on the theory of planned behaviorHelen McTaggart-Cowan, Colene Bentley, Adam Raymakers, et al.
Australia and New Zealand Health Policy|August 23, 2005
Strengthening Medicare: will increasing the bulk-billing rate and supply of general practitioners increase access to Medicare-funded general practitioner services and does rurality matter?Susan E Day, Katrina Alford, David Dunt, et al.
International Journal of Technology Assessment in Health Care|May 9, 2014
Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making?Don Husereau, Deborah A Marshall, Adrian R Levy, et al.
Ophthalmic Epidemiology|May 10, 2012
Utility weights for the vision-related Assessment of Quality of Life (AQoL)-7D instrumentJeff Richardson, Angelo Iezzi, Stuart Peacock, et al.
Clinical Trials (London, England)|January 11, 2019
Conducting clinical trials-costs, impacts, and the value of clinical trials networks: A scoping reviewColene Bentley, Sonya Cressman, Kim van der Hoek, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|February 24, 2015
Cost-effectiveness of therapies for melanomaKarissa M Johnston, Emily McPherson, Katherine Osenenko, et al.
Lung Cancer (Amsterdam, Netherlands)|January 10, 2012
Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysisIan Cromwell, Kimberly van der Hoek, Suzanne C Malfair Taylor, et al.
Investigative Ophthalmology & Visual Science|October 27, 2005
Vision and quality of life: the development of a utility measureRoseanne Misajon, Graeme Hawthorne, Jeff Richardson, et al.
Pageof 14

Showing results (31-40 of 135) with videos related to

Sort By:
Pageof 14
Pharmacoeconomics - Open|October 11, 2023
Real-World Cost Effectiveness of a Policy of KRAS Testing to Inform Cetuximab or Panitumumab for Third-Line Therapy of Metastatic Colorectal Cancer in British Columbia, CanadaReka E Pataky, Stirling Bryan, Mohsen Sadatsafavi, et al.
BMC Health Services Research|November 2, 2018
Long-term effects of cancer on earnings of childhood, adolescent and young adult cancer survivors - a population-based study from British Columbia, CanadaPaulos Teckle, Stuart Peacock, Mary L McBride, et al.
Cancer Medicine|October 17, 2020
Understanding cancer survivors' reasons to medicate with cannabis: A qualitative study based on the theory of planned behaviorHelen McTaggart-Cowan, Colene Bentley, Adam Raymakers, et al.
Australia and New Zealand Health Policy|August 23, 2005
Strengthening Medicare: will increasing the bulk-billing rate and supply of general practitioners increase access to Medicare-funded general practitioner services and does rurality matter?Susan E Day, Katrina Alford, David Dunt, et al.
International Journal of Technology Assessment in Health Care|May 9, 2014
Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making?Don Husereau, Deborah A Marshall, Adrian R Levy, et al.
Ophthalmic Epidemiology|May 10, 2012
Utility weights for the vision-related Assessment of Quality of Life (AQoL)-7D instrumentJeff Richardson, Angelo Iezzi, Stuart Peacock, et al.
Clinical Trials (London, England)|January 11, 2019
Conducting clinical trials-costs, impacts, and the value of clinical trials networks: A scoping reviewColene Bentley, Sonya Cressman, Kim van der Hoek, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|February 24, 2015
Cost-effectiveness of therapies for melanomaKarissa M Johnston, Emily McPherson, Katherine Osenenko, et al.
Lung Cancer (Amsterdam, Netherlands)|January 10, 2012
Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysisIan Cromwell, Kimberly van der Hoek, Suzanne C Malfair Taylor, et al.
Investigative Ophthalmology & Visual Science|October 27, 2005
Vision and quality of life: the development of a utility measureRoseanne Misajon, Graeme Hawthorne, Jeff Richardson, et al.
Pageof 14